Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO(BMY) · Entity 1662 | President, U.S. Primary Care | September 10, 2003 | September 12, 2003 |
| PRECIGEN, INC.PGEN · Entity 4356 | Director | March 14, 2024 | March 18, 2024 |
| Praxis Precision Medicines, Inc.PRAX · Entity 3538 | Director | June 10, 2026 | June 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BRISTOL MYERS SQUIBB CO
Report date September 10, 2003 · Filed September 12, 2003
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.10 par valueSEC Table I · non-derivative | Direct | 60,000 |
Reported balance
After 2003-09-10 transaction · row 1
1 source rowRow 1 · 2003-09-10 · Grant · Acquired 10,000 · Balance 60,000 F1: Shares consist of restricted stock with one-third vesting on each of the third, fourth and fifth anniversaries of the grant date. |
| Common Stock, $0.10 par valueSEC Table I · non-derivative | IndirectBy BMY Savings & Investment Program | 567.86 |
Reported balance
Holding disclosure · report date 2003-09-10 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 567.86 F2: Based on a plan statement as of the end of the most recent fiscal quarter. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares consist of restricted stock with one-third vesting on each of the third, fourth and fifth anniversaries of the grant date.
F2: Based on a plan statement as of the end of the most recent fiscal quarter.
PRECIGEN, INC.
Report date March 14, 2024 · Filed March 18, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 503,183 |
Reported balance
After 2024-03-14 transaction · row 1
1 source rowRow 1 · 2024-03-14 · Grant · Acquired 39,510 · Balance 503,183 F1: The shares were issued to the reporting person in lieu of an annual retainer of $56,499. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 87,412 |
Reported balance
After 2024-03-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-03-14 · Grant · Acquired 87,412 · Balance 87,412 F2: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock. F3: The RSUs vest in full on March 14, 2025. |
| Option to Purchase Common Stock (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.43 · Expires 2034-03-14 | Direct | 101,626 |
Reported balance
After 2024-03-14 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-03-14 · Grant · Acquired 101,626 · Balance 101,626 |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were issued to the reporting person in lieu of an annual retainer of $56,499.
F2: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock.
F3: The RSUs vest in full on March 14, 2025.
Praxis Precision Medicines, Inc.
Report date June 10, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 18,622 |
Reported balance
After 2026-06-10 transaction · row 1
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 1,371 · Balance 18,622 F1: Mr. Mitchell was awarded 1,371 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units vest in a single annual installment on the earlier of (i) June 10, 2027 or (ii) the date of the Issuer's 2027 annual meeting of stockholders. The restricted stock units may be settled only by delivering shares of the Issuer's common stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $240.66 · Expires 2036-06-10 | Direct | 648 |
Reported balance
After 2026-06-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-10 · Grant · Acquired 648 · Balance 648 F2: The shares subject to this option shall vest in twelve (12) equal monthly installments occurring on the 10th day of each month, with the first such installment occurring on July 10, 2026 and the final such installment occurring on the earlier of (i) June 10, 2027 or (ii) the date of the Issuer's 2027 annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Mr. Mitchell was awarded 1,371 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units vest in a single annual installment on the earlier of (i) June 10, 2027 or (ii) the date of the Issuer's 2027 annual meeting of stockholders. The restricted stock units may be settled only by delivering shares of the Issuer's common stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.
F2: The shares subject to this option shall vest in twelve (12) equal monthly installments occurring on the 10th day of each month, with the first such installment occurring on July 10, 2026 and the final such installment occurring on the earlier of (i) June 10, 2027 or (ii) the date of the Issuer's 2027 annual meeting of stockholders.
Past disclosures · reporting ended (3)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ImmunoGen, Inc.
Report date February 12, 2024 · Filed February 12, 2024
Section 16 reporting ended · disclosed 2024-02-12. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-02-12 transaction · row 1
1 source rowRow 1 · 2024-02-12 · Disposition to issuer · Disposed 103,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated November 30, 2023, by and among the Issuer, AbbVie Inc., a Delaware corporation ("AbbVie"), Athene Subsidiary LLC, a Delaware limited liability company and wholly owned subsidiary of AbbVie ("Intermediate Sub"), and Athene Merger Sub Inc., a Massachusetts corporation and wholly owned subsidiary of Intermediate Sub ("Purchaser"), pursuant to which Purchaser merged with and into the Issuer with the Issuer continuing as the surviving corporation (the "Merger"). At the effective time of the Merger (the "Effective Time"), each share of common stock, par value $.01 per share, of the Issuer (the "Common Stock"), that was issued and outstanding immediately prior to the Effective Time was converted into the right to receive an amount in cash equal to $31.26, without interest (the "Merger Consideration"). |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2024-02-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-02-12 · Disposition to issuer · Disposed 13,090 · Balance 0 F2: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit ("RSU") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such RSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration. |
| Deferred Share UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2024-02-12 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-02-12 · Disposition to issuer · Disposed 142,667 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each deferred share unit ("DSU") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such DSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such DSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.10 · Expires 2024-11-11 | Direct | 0 |
Reported balance
After 2024-02-12 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-02-12 · Disposition to issuer · Disposed 10,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.07 · Expires 2025-11-10 | Direct | 0 |
Reported balance
After 2024-02-12 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-02-12 · Disposition to issuer · Disposed 10,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.21 · Expires 2028-06-20 | Direct | 0 |
Reported balance
After 2024-02-12 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2024-02-12 · Disposition to issuer · Disposed 18,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.77 · Expires 2031-06-16 | Direct | 0 |
Reported balance
After 2024-02-12 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2024-02-12 · Disposition to issuer · Disposed 44,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.37 · Expires 2032-06-15 | Direct | 0 |
Reported balance
After 2024-02-12 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2024-02-12 · Disposition to issuer · Disposed 44,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.72 · Expires 2033-06-14 | Direct | 0 |
Reported balance
After 2024-02-12 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2024-02-12 · Disposition to issuer · Disposed 19,597 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated November 30, 2023, by and among the Issuer, AbbVie Inc., a Delaware corporation ("AbbVie"), Athene Subsidiary LLC, a Delaware limited liability company and wholly owned subsidiary of AbbVie ("Intermediate Sub"), and Athene Merger Sub Inc., a Massachusetts corporation and wholly owned subsidiary of Intermediate Sub ("Purchaser"), pursuant to which Purchaser merged with and into the Issuer with the Issuer continuing as the surviving corporation (the "Merger"). At the effective time of the Merger (the "Effective Time"), each share of common stock, par value $.01 per share, of the Issuer (the "Common Stock"), that was issued and outstanding immediately prior to the Effective Time was converted into the right to receive an amount in cash equal to $31.26, without interest (the "Merger Consideration").
F2: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit ("RSU") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such RSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration.
F3: Pursuant to the Merger Agreement, at the Effective Time, each deferred share unit ("DSU") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such DSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such DSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration.
F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option.
Kinnate Biopharma Inc.
Report date April 03, 2024 · Filed April 05, 2024
Section 16 reporting ended · disclosed 2024-04-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.63 · Expires 2030-08-18 | Direct | 0 |
Reported balance
After 2024-04-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-04-03 · Disposition to issuer · Disposed 121,503 · Balance 0 F1: This option was cancelled pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the "Merger Agreement") in exchange for one non-transferable contingent value right ("CVR") for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.46 · Expires 2031-06-11 | Direct | 0 |
Reported balance
After 2024-04-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-04-03 · Disposition to issuer · Disposed 20,250 · Balance 0 F1: This option was cancelled pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the "Merger Agreement") in exchange for one non-transferable contingent value right ("CVR") for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.38 · Expires 2032-06-13 | Direct | 0 |
Reported balance
After 2024-04-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-04-03 · Disposition to issuer · Disposed 20,250 · Balance 0 F1: This option was cancelled pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the "Merger Agreement") in exchange for one non-transferable contingent value right ("CVR") for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.48 · Expires 2033-06-12 | Direct | 0 |
Reported balance
After 2024-04-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-04-03 · Disposition to issuer · Disposed 25,000 · Balance 0 F1: This option was cancelled pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the "Merger Agreement") in exchange for one non-transferable contingent value right ("CVR") for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was cancelled pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the "Merger Agreement") in exchange for one non-transferable contingent value right ("CVR") for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount.
Theravance Biopharma, Inc.
Report date September 23, 2026 · Filed September 25, 2026
Section 16 reporting ended · disclosed 2026-09-25. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2026-09-23 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-23 · Disposition to issuer · Disposed 91,204 · Balance 6,009 F1: On September 23, 2026, pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated June 28, 2026, by and among the Issuer, Zymeworks Inc. ("Parent"), and Zymeworks Merger Sub 1, a wholly owned subsidiary of Parent, the Issuer became a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger (the "Effective Time"), pursuant to the Merger Agreement, each ordinary share, par value $0.00001 per share, of the Issuer ("Ordinary Share") held by the reporting person as of immediately prior to the Effective Time was cancelled and converted into the right to receive (i) $17.00 in cash, without interest (the "Per Share Cash Consideration") and (ii) one contingent value right (a "CVR"). Each CVR represents a non-tradeable contractual contingent right to receive cash payments based on the achievement of certain commercial milestones following the Effective Time. Row 2 · 2026-09-23 · Disposition to issuer · Disposed 6,009 · Balance 0 F2: At the Effective Time, pursuant to the Merger Agreement, each award of restricted stock units of the Issuer (a "Company RSU Award") that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the Per Share Cash Consideration multiplied by (ii) the number of Ordinary Shares underlying such Company RSU Award (subject to any required tax withholdings as provided in the Merger Agreement) plus (iii) one CVR for each Ordinary Share underlying such Company RSU Award. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.43 · Expires 2028-04-30 | Direct | 0 |
Reported balance
After 2026-09-23 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-23 · Disposition to issuer · Disposed 6,000 · Balance 0 F3: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.85 · Expires 2029-04-29 | Direct | 0 |
Reported balance
After 2026-09-23 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-09-23 · Disposition to issuer · Disposed 6,000 · Balance 0 F3: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.14 · Expires 2030-04-27 | Direct | 0 |
Reported balance
After 2026-09-23 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-09-23 · Disposition to issuer · Disposed 6,000 · Balance 0 F3: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.35 · Expires 2031-04-26 | Direct | 0 |
Reported balance
After 2026-09-23 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-09-23 · Disposition to issuer · Disposed 6,000 · Balance 0 F3: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.15 · Expires 2032-04-25 | Direct | 0 |
Reported balance
After 2026-09-23 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-09-23 · Disposition to issuer · Disposed 28,000 · Balance 0 F3: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.95 · Expires 2033-05-01 | Direct | 0 |
Reported balance
After 2026-09-23 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-09-23 · Disposition to issuer · Disposed 22,044 · Balance 0 F3: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.49 · Expires 2034-05-07 | Direct | 0 |
Reported balance
After 2026-09-23 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-09-23 · Disposition to issuer · Disposed 23,576 · Balance 0 F3: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.39 · Expires 2035-05-18 | Direct | 0 |
Reported balance
After 2026-09-23 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-09-23 · Disposition to issuer · Disposed 24,258 · Balance 0 F3: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.64 · Expires 2036-06-11 | Direct | 0 |
Reported balance
After 2026-09-23 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-09-23 · Disposition to issuer · Disposed 13,398 · Balance 0 F3: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor. |
Filing footnotes · ownership attribution and instrument terms
F1: On September 23, 2026, pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated June 28, 2026, by and among the Issuer, Zymeworks Inc. ("Parent"), and Zymeworks Merger Sub 1, a wholly owned subsidiary of Parent, the Issuer became a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger (the "Effective Time"), pursuant to the Merger Agreement, each ordinary share, par value $0.00001 per share, of the Issuer ("Ordinary Share") held by the reporting person as of immediately prior to the Effective Time was cancelled and converted into the right to receive (i) $17.00 in cash, without interest (the "Per Share Cash Consideration") and (ii) one contingent value right (a "CVR"). Each CVR represents a non-tradeable contractual contingent right to receive cash payments based on the achievement of certain commercial milestones following the Effective Time.
F2: At the Effective Time, pursuant to the Merger Agreement, each award of restricted stock units of the Issuer (a "Company RSU Award") that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the Per Share Cash Consideration multiplied by (ii) the number of Ordinary Shares underlying such Company RSU Award (subject to any required tax withholdings as provided in the Merger Agreement) plus (iii) one CVR for each Ordinary Share underlying such Company RSU Award.
F3: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 23, 2026 Filed Sep 25, 2026 00:32 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Disposition to issuerShare Option (Right to Buy) · Derivative | 13,398 | Not disclosed Strike: $16.64 | Not disclosed |
DisclosureSEC source: 0001199297-26-000006 · form4-09252026_120934.xml · derivative · entry 11 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 13,398 shares Expires 2036-06-11 F3 · price: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor. F3 · derivative.exercise_date: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor. Read SEC document |
| September 23, 2026 Filed Sep 25, 2026 00:32 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Disposition to issuerShare Option (Right to Buy) · Derivative | 24,258 | Not disclosed Strike: $9.39 | Not disclosed |
DisclosureSEC source: 0001199297-26-000006 · form4-09252026_120934.xml · derivative · entry 10 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 24,258 shares Expires 2035-05-18 F3 · price: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor. F3 · derivative.exercise_date: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor. Read SEC document |
| September 23, 2026 Filed Sep 25, 2026 00:32 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Disposition to issuerShare Option (Right to Buy) · Derivative | 23,576 | Not disclosed Strike: $9.49 | Not disclosed |
DisclosureSEC source: 0001199297-26-000006 · form4-09252026_120934.xml · derivative · entry 9 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 23,576 shares Expires 2034-05-07 F3 · price: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor. F3 · derivative.exercise_date: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor. Read SEC document |
| September 23, 2026 Filed Sep 25, 2026 00:32 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Disposition to issuerShare Option (Right to Buy) · Derivative | 22,044 | Not disclosed Strike: $10.95 | Not disclosed |
DisclosureSEC source: 0001199297-26-000006 · form4-09252026_120934.xml · derivative · entry 8 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 22,044 shares Expires 2033-05-01 F3 · price: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor. F3 · derivative.exercise_date: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor. Read SEC document |
| September 23, 2026 Filed Sep 25, 2026 00:32 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Disposition to issuerShare Option (Right to Buy) · Derivative | 28,000 | Not disclosed Strike: $10.15 | Not disclosed |
DisclosureSEC source: 0001199297-26-000006 · form4-09252026_120934.xml · derivative · entry 7 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 28,000 shares Expires 2032-04-25 F3 · price: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor. F3 · derivative.exercise_date: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor. Read SEC document |
| September 23, 2026 Filed Sep 25, 2026 00:32 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Disposition to issuerShare Option (Right to Buy) · Derivative | 6,000 | Not disclosed Strike: $20.35 | Not disclosed |
DisclosureSEC source: 0001199297-26-000006 · form4-09252026_120934.xml · derivative · entry 6 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 6,000 shares Expires 2031-04-26 F3 · price: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor. F3 · derivative.exercise_date: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor. Read SEC document |
| September 23, 2026 Filed Sep 25, 2026 00:32 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Disposition to issuerShare Option (Right to Buy) · Derivative | 6,000 | Not disclosed Strike: $30.14 | Not disclosed |
DisclosureSEC source: 0001199297-26-000006 · form4-09252026_120934.xml · derivative · entry 5 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 6,000 shares Expires 2030-04-27 F3 · price: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor. F3 · derivative.exercise_date: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor. Read SEC document |
| September 23, 2026 Filed Sep 25, 2026 00:32 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Disposition to issuerShare Option (Right to Buy) · Derivative | 6,000 | Not disclosed Strike: $23.85 | Not disclosed |
DisclosureSEC source: 0001199297-26-000006 · form4-09252026_120934.xml · derivative · entry 4 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 6,000 shares Expires 2029-04-29 F3 · price: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor. F3 · derivative.exercise_date: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor. Read SEC document |
| September 23, 2026 Filed Sep 25, 2026 00:32 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Disposition to issuerShare Option (Right to Buy) · Derivative | 6,000 | Not disclosed Strike: $24.43 | Not disclosed |
DisclosureSEC source: 0001199297-26-000006 · form4-09252026_120934.xml · derivative · entry 3 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 6,000 shares Expires 2028-04-30 F3 · price: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor. F3 · derivative.exercise_date: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor. Read SEC document |
| September 23, 2026 Filed Sep 25, 2026 00:32 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Disposition to issuerOrdinary Shares | 6,009 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001199297-26-000006 · form4-09252026_120934.xml · nonDerivative · entry 2 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F2 · price: At the Effective Time, pursuant to the Merger Agreement, each award of restricted stock units of the Issuer (a "Company RSU Award") that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the Per Share Cash Consideration multiplied by (ii) the number of Ordinary Shares underlying such Company RSU Award (subject to any required tax withholdings as provided in the Merger Agreement) plus (iii) one CVR for each Ordinary Share underlying such Company RSU Award. Read SEC document |
| September 23, 2026 Filed Sep 25, 2026 00:32 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Disposition to issuerOrdinary Shares | 91,204 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001199297-26-000006 · form4-09252026_120934.xml · nonDerivative · entry 1 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,009 F1 · price: On September 23, 2026, pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated June 28, 2026, by and among the Issuer, Zymeworks Inc. ("Parent"), and Zymeworks Merger Sub 1, a wholly owned subsidiary of Parent, the Issuer became a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger (the "Effective Time"), pursuant to the Merger Agreement, each ordinary share, par value $0.00001 per share, of the Issuer ("Ordinary Share") held by the reporting person as of immediately prior to the Effective Time was cancelled and converted into the right to receive (i) $17.00 in cash, without interest (the "Per Share Cash Consideration") and (ii) one contingent value right (a "CVR"). Each CVR represents a non-tradeable contractual contingent right to receive cash payments based on the achievement of certain commercial milestones following the Effective Time. Read SEC document |
| June 12, 2026 Filed Jun 17, 2026 01:37 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantShare Option (Right to Buy) · Derivative | 13,398 | $0.00 Strike: $16.64 | $0.00 |
DisclosureSEC source: 0001199297-26-000003 · form4-06172026_010636.xml · derivative · entry 2 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,398 Underlying: Ordinary Shares · 13,398 shares Expires 2036-06-11 F1 · derivative.exercise_date: This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the company's shareholders provided the optionee remains in continuous service on such date. Read SEC document |
| June 12, 2026 Filed Jun 17, 2026 01:37 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 6,009 | $0.00 | $0.00 |
DisclosureSEC source: 0001199297-26-000003 · form4-06172026_010636.xml · nonDerivative · entry 1 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,213 Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 21:23 UTC | Praxis Precision Medicines, Inc. PRAX · Entity 3538 | GrantStock Option (Right to Buy) · Derivative | 648 | $0.00 Strike: $240.66 | $0.00 |
DisclosureSEC source: 0001689548-26-000059 · wk-form4_1781299435.xml · derivative · entry 2 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 648 Underlying: Common Stock · 648 shares Expires 2036-06-10 F2 · derivative.exercise_date: The shares subject to this option shall vest in twelve (12) equal monthly installments occurring on the 10th day of each month, with the first such installment occurring on July 10, 2026 and the final such installment occurring on the earlier of (i) June 10, 2027 or (ii) the date of the Issuer's 2027 annual meeting of stockholders. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 21:23 UTC | Praxis Precision Medicines, Inc. PRAX · Entity 3538 | GrantCommon Stock | 1,371 | $0.00 | $0.00 |
DisclosureSEC source: 0001689548-26-000059 · wk-form4_1781299435.xml · nonDerivative · entry 1 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,622 F1 · kind: Mr. Mitchell was awarded 1,371 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units vest in a single annual installment on the earlier of (i) June 10, 2027 or (ii) the date of the Issuer's 2027 annual meeting of stockholders. The restricted stock units may be settled only by delivering shares of the Issuer's common stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document |
| September 24, 2025 Filed Sep 25, 2025 20:40 UTC | Praxis Precision Medicines, Inc. PRAX · Entity 3538 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,753 | $0.00 Strike: $44.04 | $0.00 |
DisclosureSEC source: 0001689548-25-000096 · wk-form4_1758832845.xml · derivative · entry 6 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,767 Underlying: Common Stock · 1,753 shares Expires 2035-06-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to this option vest in twelve (12) equal monthly installments over one (1) year commencing on June 26, 2025. Read SEC document |
| September 24, 2025 Filed Sep 25, 2025 20:40 UTC | Praxis Precision Medicines, Inc. PRAX · Entity 3538 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,566 | $0.00 Strike: $44.25 | $0.00 |
DisclosureSEC source: 0001689548-25-000096 · wk-form4_1758832845.xml · derivative · entry 5 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,566 shares Expires 2034-06-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option was fully vested as of June 5, 2025. Read SEC document |
| September 24, 2025 Filed Sep 25, 2025 20:40 UTC | Praxis Precision Medicines, Inc. PRAX · Entity 3538 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,932 | $0.00 Strike: $14.36 | $0.00 |
DisclosureSEC source: 0001689548-25-000096 · wk-form4_1758832845.xml · derivative · entry 4 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,932 shares Expires 2033-06-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option was fully vested as of June 12, 2024. Read SEC document |
| September 24, 2025 Filed Sep 25, 2025 20:40 UTC | Praxis Precision Medicines, Inc. PRAX · Entity 3538 | Exercise / conversionCommon Stock | 1,753 | $44.04 | $77,202.12 |
DisclosureSEC source: 0001689548-25-000096 · wk-form4_1758832845.xml · nonDerivative · entry 3 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,251 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 24, 2025 Filed Sep 25, 2025 20:40 UTC | Praxis Precision Medicines, Inc. PRAX · Entity 3538 | Exercise / conversionCommon Stock | 8,566 | $44.25 | $379,045.50 |
DisclosureSEC source: 0001689548-25-000096 · wk-form4_1758832845.xml · nonDerivative · entry 2 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,498 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 24, 2025 Filed Sep 25, 2025 20:40 UTC | Praxis Precision Medicines, Inc. PRAX · Entity 3538 | Exercise / conversionCommon Stock | 1,932 | $14.36 | $27,743.52 |
DisclosureSEC source: 0001689548-25-000096 · wk-form4_1758832845.xml · nonDerivative · entry 1 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,932 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 26, 2025 Filed Jun 27, 2025 20:55 UTC | Praxis Precision Medicines, Inc. PRAX · Entity 3538 | GrantStock Option (Right to Buy) · Derivative | 10,520 | $0.00 Strike: $44.04 | $0.00 |
DisclosureSEC source: 0001689548-25-000081 · wk-form4_1751057725.xml · derivative · entry 1 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,520 Underlying: Common Stock · 10,520 shares Expires 2035-06-26 F1 · derivative.exercise_date: The shares subject to this option shall vest in twelve (12) equal monthly installments over one (1) year commencing on June 26, 2025. Read SEC document |
| May 19, 2025 Filed May 21, 2025 23:15 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantShare Option (Right to Buy) · Derivative | 24,258 | $0.00 Strike: $9.39 | $0.00 |
DisclosureSEC source: 0001415889-25-014015 · form4-05212025_110547.xml · derivative · entry 2 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,258 Underlying: Ordinary Shares · 24,258 shares Expires 2035-05-18 F1 · derivative.exercise_date: This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the company's shareholders provided the optionee remains in continuous service on such date. Read SEC document |
| May 19, 2025 Filed May 21, 2025 23:15 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 10,649 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-014015 · form4-05212025_110547.xml · nonDerivative · entry 1 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,204 Read SEC document |
| June 05, 2024 Filed Jun 6, 2024 22:56 UTC | Praxis Precision Medicines, Inc. PRAX · Entity 3538 | GrantStock Option (Right to Buy) · Derivative | 8,566 | $0.00 Strike: $44.25 | $0.00 |
DisclosureSEC source: 0001689548-24-000078 · wk-form4_1717714567.xml · derivative · entry 1 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,566 Underlying: Common Stock · 8,566 shares Expires 2034-06-05 F1 · derivative.exercise_date: The shares subject to this option shall vest in twelve (12) equal monthly installments over one (1) year commencing on June 5, 2024. Read SEC document |
| May 08, 2024 Filed May 10, 2024 22:09 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantShare Option (Right to Buy) · Derivative | 23,576 | $0.00 Strike: $9.49 | $0.00 |
DisclosureSEC source: 0001415889-24-012915 · form4-05102024_100546.xml · derivative · entry 2 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,576 Underlying: Ordinary Shares · 23,576 shares Expires 2034-05-07 F1 · derivative.exercise_date: This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the company's shareholders provided the optionee remains in continuous service on such date. Read SEC document |
| May 08, 2024 Filed May 10, 2024 22:09 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 10,537 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-012915 · form4-05102024_100546.xml · nonDerivative · entry 1 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,555 Read SEC document |
| April 03, 2024 Filed Apr 5, 2024 16:55 UTC | Kinnate Biopharma Inc. KNTE · Entity 92187 | Disposition to issuerStock Option (right to buy) · Derivative | 25,000 | Not disclosed Strike: $3.48 | Not disclosed |
DisclosureSEC source: 0001415889-24-010432 · form4-04052024_040425.xml · derivative · entry 4 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2033-06-12 F1 · price: This option was cancelled pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the "Merger Agreement") in exchange for one non-transferable contingent value right ("CVR") for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount. F1 · derivative.exercise_date: This option was cancelled pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the "Merger Agreement") in exchange for one non-transferable contingent value right ("CVR") for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount. Read SEC document |
| April 03, 2024 Filed Apr 5, 2024 16:55 UTC | Kinnate Biopharma Inc. KNTE · Entity 92187 | Disposition to issuerStock Option (right to buy) · Derivative | 20,250 | Not disclosed Strike: $8.38 | Not disclosed |
DisclosureSEC source: 0001415889-24-010432 · form4-04052024_040425.xml · derivative · entry 3 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,250 shares Expires 2032-06-13 F1 · price: This option was cancelled pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the "Merger Agreement") in exchange for one non-transferable contingent value right ("CVR") for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount. F1 · derivative.exercise_date: This option was cancelled pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the "Merger Agreement") in exchange for one non-transferable contingent value right ("CVR") for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount. Read SEC document |
| April 03, 2024 Filed Apr 5, 2024 16:55 UTC | Kinnate Biopharma Inc. KNTE · Entity 92187 | Disposition to issuerStock Option (right to buy) · Derivative | 20,250 | Not disclosed Strike: $24.46 | Not disclosed |
DisclosureSEC source: 0001415889-24-010432 · form4-04052024_040425.xml · derivative · entry 2 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,250 shares Expires 2031-06-11 F1 · price: This option was cancelled pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the "Merger Agreement") in exchange for one non-transferable contingent value right ("CVR") for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount. F1 · derivative.exercise_date: This option was cancelled pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the "Merger Agreement") in exchange for one non-transferable contingent value right ("CVR") for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount. Read SEC document |
| April 03, 2024 Filed Apr 5, 2024 16:55 UTC | Kinnate Biopharma Inc. KNTE · Entity 92187 | Disposition to issuerStock Option (right to buy) · Derivative | 121,503 | Not disclosed Strike: $5.63 | Not disclosed |
DisclosureSEC source: 0001415889-24-010432 · form4-04052024_040425.xml · derivative · entry 1 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 121,503 shares Expires 2030-08-18 F1 · price: This option was cancelled pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the "Merger Agreement") in exchange for one non-transferable contingent value right ("CVR") for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount. F1 · derivative.exercise_date: This option was cancelled pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the "Merger Agreement") in exchange for one non-transferable contingent value right ("CVR") for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount. Read SEC document |
| March 14, 2024 Filed Mar 18, 2024 22:14 UTC | PRECIGEN, INC. PGEN · Entity 4356 | GrantOption to Purchase Common Stock (Right to Buy) · Derivative | 101,626 | $0.00 Strike: $1.43 | $0.00 |
DisclosureSEC source: 0000950103-24-003951 · dp208510_4-mitchell.xml · derivative · entry 3 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,626 Underlying: Common Stock · 101,626 shares Expires 2034-03-14 Read SEC document |
| March 14, 2024 Filed Mar 18, 2024 22:14 UTC | PRECIGEN, INC. PGEN · Entity 4356 | GrantRestricted Stock Units · Derivative | 87,412 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-24-003951 · dp208510_4-mitchell.xml · derivative · entry 2 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,412 Underlying: Common Stock · 87,412 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock. F3 · derivative.exercise_date: The RSUs vest in full on March 14, 2025. F3 · derivative.expiration_date: The RSUs vest in full on March 14, 2025. Read SEC document |
| March 14, 2024 Filed Mar 18, 2024 22:14 UTC | PRECIGEN, INC. PGEN · Entity 4356 | GrantCommon Stock | 39,510 | $1.43 | $56,499.30 |
DisclosureSEC source: 0000950103-24-003951 · dp208510_4-mitchell.xml · nonDerivative · entry 1 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 503,183 F1 · price: The shares were issued to the reporting person in lieu of an annual retainer of $56,499. Read SEC document |
| March 09, 2024 Filed Mar 12, 2024 23:54 UTC | PRECIGEN, INC. PGEN · Entity 4356 | Exercise / conversionRestricted Stock Units · Derivative | 106,837 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-24-003747 · dp208301_4-mitchell.xml · derivative · entry 2 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 106,837 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock. F2 · derivative.exercise_date: The RSUs vested in full on March 9, 2024. F2 · derivative.expiration_date: The RSUs vested in full on March 9, 2024. Read SEC document |
| March 09, 2024 Filed Mar 12, 2024 23:54 UTC | PRECIGEN, INC. PGEN · Entity 4356 | Exercise / conversionCommon Stock | 106,837 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950103-24-003747 · dp208301_4-mitchell.xml · nonDerivative · entry 1 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 463,673 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock. Read SEC document |
| February 12, 2024 Filed Feb 12, 2024 16:48 UTC | ImmunoGen, Inc. IMGN · Entity 94428 | Disposition to issuerStock Option (Right to Buy) · Derivative | 19,597 | Not disclosed Strike: $17.72 | Not disclosed |
DisclosureSEC source: 0001104659-24-014721 · tm245865-16_4seq1.xml · derivative · entry 9 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,597 shares Expires 2033-06-14 F4 · kind: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option. F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option. Read SEC document |
| February 12, 2024 Filed Feb 12, 2024 16:48 UTC | ImmunoGen, Inc. IMGN · Entity 94428 | Disposition to issuerStock Option (Right to Buy) · Derivative | 44,000 | Not disclosed Strike: $3.37 | Not disclosed |
DisclosureSEC source: 0001104659-24-014721 · tm245865-16_4seq1.xml · derivative · entry 8 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 44,000 shares Expires 2032-06-15 F4 · kind: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option. F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option. Read SEC document |
| February 12, 2024 Filed Feb 12, 2024 16:48 UTC | ImmunoGen, Inc. IMGN · Entity 94428 | Disposition to issuerStock Option (Right to Buy) · Derivative | 44,000 | Not disclosed Strike: $6.77 | Not disclosed |
DisclosureSEC source: 0001104659-24-014721 · tm245865-16_4seq1.xml · derivative · entry 7 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 44,000 shares Expires 2031-06-16 F4 · kind: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option. F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option. Read SEC document |
| February 12, 2024 Filed Feb 12, 2024 16:48 UTC | ImmunoGen, Inc. IMGN · Entity 94428 | Disposition to issuerStock Option (Right to Buy) · Derivative | 18,000 | Not disclosed Strike: $11.21 | Not disclosed |
DisclosureSEC source: 0001104659-24-014721 · tm245865-16_4seq1.xml · derivative · entry 6 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,000 shares Expires 2028-06-20 F4 · kind: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option. F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option. Read SEC document |
| February 12, 2024 Filed Feb 12, 2024 16:48 UTC | ImmunoGen, Inc. IMGN · Entity 94428 | Disposition to issuerStock Option (Right to Buy) · Derivative | 10,000 | Not disclosed Strike: $13.07 | Not disclosed |
DisclosureSEC source: 0001104659-24-014721 · tm245865-16_4seq1.xml · derivative · entry 5 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2025-11-10 F4 · kind: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option. F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option. Read SEC document |
| February 12, 2024 Filed Feb 12, 2024 16:48 UTC | ImmunoGen, Inc. IMGN · Entity 94428 | Disposition to issuerStock Option (Right to Buy) · Derivative | 10,000 | Not disclosed Strike: $10.10 | Not disclosed |
DisclosureSEC source: 0001104659-24-014721 · tm245865-16_4seq1.xml · derivative · entry 4 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2024-11-11 F4 · kind: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option. F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option. Read SEC document |
| February 12, 2024 Filed Feb 12, 2024 16:48 UTC | ImmunoGen, Inc. IMGN · Entity 94428 | Disposition to issuerDeferred Share Unit · Derivative | 142,667 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0001104659-24-014721 · tm245865-16_4seq1.xml · derivative · entry 3 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 142,667 shares Expires not disclosed F3 · derivative.exercise_price: Pursuant to the Merger Agreement, at the Effective Time, each deferred share unit ("DSU") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such DSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such DSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration. F3 · kind: Pursuant to the Merger Agreement, at the Effective Time, each deferred share unit ("DSU") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such DSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such DSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration. F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each deferred share unit ("DSU") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such DSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such DSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each deferred share unit ("DSU") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such DSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such DSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each deferred share unit ("DSU") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such DSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such DSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration. Read SEC document |
| February 12, 2024 Filed Feb 12, 2024 16:48 UTC | ImmunoGen, Inc. IMGN · Entity 94428 | Disposition to issuerRestricted Stock Unit · Derivative | 13,090 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0001104659-24-014721 · tm245865-16_4seq1.xml · derivative · entry 2 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,090 shares Expires not disclosed F2 · derivative.exercise_price: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit ("RSU") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such RSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration. F2 · kind: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit ("RSU") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such RSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration. F2 · price: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit ("RSU") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such RSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit ("RSU") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such RSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration. F2 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit ("RSU") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such RSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration. Read SEC document |
| February 12, 2024 Filed Feb 12, 2024 16:48 UTC | ImmunoGen, Inc. IMGN · Entity 94428 | Disposition to issuerCommon Stock | 103,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-014721 · tm245865-16_4seq1.xml · nonDerivative · entry 1 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated November 30, 2023, by and among the Issuer, AbbVie Inc., a Delaware corporation ("AbbVie"), Athene Subsidiary LLC, a Delaware limited liability company and wholly owned subsidiary of AbbVie ("Intermediate Sub"), and Athene Merger Sub Inc., a Massachusetts corporation and wholly owned subsidiary of Intermediate Sub ("Purchaser"), pursuant to which Purchaser merged with and into the Issuer with the Issuer continuing as the surviving corporation (the "Merger"). At the effective time of the Merger (the "Effective Time"), each share of common stock, par value $.01 per share, of the Issuer (the "Common Stock"), that was issued and outstanding immediately prior to the Effective Time was converted into the right to receive an amount in cash equal to $31.26, without interest (the "Merger Consideration"). F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated November 30, 2023, by and among the Issuer, AbbVie Inc., a Delaware corporation ("AbbVie"), Athene Subsidiary LLC, a Delaware limited liability company and wholly owned subsidiary of AbbVie ("Intermediate Sub"), and Athene Merger Sub Inc., a Massachusetts corporation and wholly owned subsidiary of Intermediate Sub ("Purchaser"), pursuant to which Purchaser merged with and into the Issuer with the Issuer continuing as the surviving corporation (the "Merger"). At the effective time of the Merger (the "Effective Time"), each share of common stock, par value $.01 per share, of the Issuer (the "Common Stock"), that was issued and outstanding immediately prior to the Effective Time was converted into the right to receive an amount in cash equal to $31.26, without interest (the "Merger Consideration"). Read SEC document |
| September 22, 2023 Filed Sep 25, 2023 20:02 UTC | PRECIGEN, INC. PGEN · Entity 4356 | PurchaseCommon Stock | 25,000 | $1.41 | $35,250.00 |
DisclosureSEC source: 0000950103-23-013963 · dp200416_4-mitchell.xml · nonDerivative · entry 1 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 356,836 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.39 to $1.44, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) this Form 4. Read SEC document |
| September 22, 2023 Filed Sep 26, 2023 16:08 UTC | ImmunoGen, Inc. IMGN · Entity 94428 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $14.70 | $0.00 |
DisclosureSEC source: 0001415889-23-013580 · form4-09262023_080933.xml · derivative · entry 2 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2023-11-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option was granted on 11/12/2013 and was exercisable as to 2,500 shares commencing on February 1, 2014, 2,500 shares commencing on May 1, 2014, 2,500 shares commencing on August 1, 2014, and 2,500 shares commencing on November 1, 2014. Read SEC document |
| September 22, 2023 Filed Sep 26, 2023 16:08 UTC | ImmunoGen, Inc. IMGN · Entity 94428 | Exercise / conversionCommon Stock | 10,000 | $14.70 | $147,000.00 |
DisclosureSEC source: 0001415889-23-013580 · form4-09262023_080933.xml · nonDerivative · entry 1 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 152,667 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 22, 2023 Filed Dec 19, 2023 19:00 UTC Amendment | ImmunoGen, Inc. IMGN · Entity 94428 | Exercise / conversionCommon Stock | 10,000 | $14.70 | $147,000.00 |
DisclosureSEC source: 0001415889-23-016755 · form4a-12202023_121207.xml · nonDerivative · entry 1 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 103,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Due to clerical error, this amendment to Form 4 is being filed to correct the number of shares beneficially owned following the reported transaction. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 16:46 UTC | ImmunoGen, Inc. IMGN · Entity 94428 | GrantStock Option (right to buy) · Derivative | 19,597 | $0.00 Strike: $17.72 | $0.00 |
DisclosureSEC source: 0001415889-23-009949 · form4-06162023_080641.xml · derivative · entry 2 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,597 Underlying: Common Stock · 19,597 shares Expires 2033-06-14 F3 · derivative.exercise_price: The stock options were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors, as amended, and the 2018 Employee, Director and Consultant Equity Incentive Plan, as amended. F4 · derivative.exercise_date: The stock options vest ratably on each of 9/1/23, 12/1/23, 3/1/24, and 6/1/24, contingent upon the individual remaining a director as of each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.